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Acute myeloid leukaemia (AML) is a clinically and molecularly heteroge-
neous disease characterised by uncontrolled proliferation, block in differen-
tiation and acquired self-renewal of hematopoietic stem and myeloid
progenitor cells. This results in the clonal expansion of myeloid blasts
within the bone marrow and peripheral blood. The incidence of AML
increases with age, and in childhood, AML accounts for 20% of all leukae-
mias. Whilst there are many clinical and biological similarities between
paediatric and adult AML with continuum across the age range, many
characteristics of AML are associated with age of disease onset. These
include chromosomal aberrations, gene mutations and differentiation lin-
eage. Following chemotherapy, AML cells that survive and result in dis-
ease relapse exist in an altered chemoresistant state. Molecular profiling
currently represents a powerful avenue of experimentation to study AML
cells from adults and children pre- and postchemotherapy as a means of
identifying prognostic biomarkers and targetable molecular vulnerabilities
that may be age-specific. This review highlights recent advances in our
knowledge of the molecular profiles with a focus on transcriptomes and
metabolomes, leukaemia stem cells and chemoresistant cells in adult and
paediatric AML and focus on areas that hold promise for future therapies.
1. Introduction
Acute myeloid leukaemia (AML) is a haematological
malignancy, with incidence rates having grown by
29% since the early 1990s (www.cancerresearchuk.
org). Incidence increases with age, and 70% of
patients diagnosed with the disease still die from this
disorder. The current overall survival rate in children
is only 60–70% and thereafter falls progressively
with age to < 5% in those aged over 65 years. Both
children and adults die within 5 years from diagnosis
due to a combination of relapse (up to 35% and
99%, respectively [1], and treatment-related mortality
[2].
To date, most studies on AML pathogenesis have
focused on adult patients. AML is characterised by
clonal expansion of myeloid blasts cells with uncon-
trolled proliferation [3]. It arises from leukaemic stem
cells (LSCs) that maintain the disease [4] and that give
rise to the clones of AML blasts. AML either develops
de novo or appears as secondary disease, subsequent to
underlying myeloproliferative neoplasms (MPN) or
myelodysplastic syndromes (MDS). Mutations
acquired over time can lead to clonal enrichment in
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the haemopoietic compartment in the absence of any
clinical manifestations termed clonal haematopoiesis
(CH). Such clones may then acquire subsequent muta-
tions transforming into malignant clones that underlie
the development of AML. In children, the vast major-
ity of patients present with de novo AML, whilst in
adults, AML more commonly arises from an underly-
ing MPN or MDS, and this characteristic increases
with age [5,6]. Further age-related sequential acquisi-
tion of mutations during the course of disease could
largely explain the clonal heterogeneity in majority of
adult AML with underlying MPN or MDS. Indeed,
accumulation of somatic mutations in haematopoietic
stem cells (HSCs) is proportional with age suggesting
that the initial mutation for AML occurs stochastically
in a cell which goes on to garner a unique combina-
tion of other AML-related mutations by chance as an
individual grows older [7]. In adults, it is possible there
already exists haematopoietic cells with leukaemia
somatic variants that are thriving as passenger lesions
[8]. These primitive mutations could influence the type
and order of further mutations and the evolution of
AML clonal heterogeneity [9]. On the other hand, the
features associated with ageing cannot be the explana-
tion for paediatric AML incidence and clonal diver-
sity. Thus, it seems the pathogenesis of AML in
children may differ to that in adults.
Biology-based ‘omics’ technologies have revolu-
tionised the field’s comprehension of AML pathogen-
esis. The first AML genome was sequenced by Tim
Ley et al. [10]. Since then, advancements in technolo-
gies have enabled genomic profiling (Box 1) down to
the single-cell level and high-throughput analysis of
large numbers of samples at an affordable cost. Dis-
tinct genetic and epigenetic alterations constitute the
clonal diversity each individual case of AML presents
[11]. The genomic information affects the unique
morphology and immunophenotypic attributes of
each clonal cell in a single AML case [12]. During
disease advancement, the prevalence of malignant
clones and subclones may change due to evolutionary
pressures [13]. Genomic profiling is highly valuable
for AML treatment strategies (Box 2), and addition-
ally, some mutations and chromosomal aberrations
are excellent for minimal residual disease (MRD)
monitoring. Transcriptomics using bulk or single-cell
RNA sequencing followed by pathway analysis is a
powerful analytical approach that can provide impor-
tant insights in AML biological and biochemical fea-
tures. This has been especially powerful in defining
stem cell populations, chemoresistance and metabolic
features of AML cells, which will be discussed further
below.
In this article, we review genetic, epigenetic, tran-
scriptional and metabolic profiles and their association
with clonal heterogeneity, whilst highlighting differ-
ences between paediatric and adult AML. Next, we
focus specifically on molecular AML profiles and
chemoresistance, as the cells that survive chemother-
apy have recently been shown to be transcriptionally
distinct from therapy-na€ıve cells. We will also consider
the molecular profiles that may be used for developing
new therapies in the context of specific populations
such as LSCs and chemoresistant cells.
2. Genetic and epigenetic profiles of
paediatric and adult AML
The genetic landscape and mutational load (Box 3) are
very different between children and adults (Fig. 1).
Only 20% of paediatric patients have a normal kary-
otype, with the majority bearing chromosomal abnor-
malities, and the number of somatic mutations in
paediatric patients is lower than in adult patients (5–6
somatic mutations per paediatric sample [5,31,32] vs
10–13 per adult genome [33,34]. Cytogenetic and
Box 1
Genomic Profiling
Genomic profiling is a technique that enables us to
explore the genetic information of an individual or in a
particular cell type and the interactions in which these
genes have with each other and the environment. The
advent of genomic methodologies from microarrays to
large scale genome sequencing has facilitated the study
of not only genes but even the subsequential transcripts
and proteins simultaneously [13]. In recent years, next-
generation sequencing (NGS) approaches such as
whole-genome sequencing and whole exome sequencing
have largely replaced the preceding techniques (reviewed
in Ref. [14]. Single-cell DNA sequencing (scDNA-seq) is
a new and promising approach for high-throughput
study of clonality in AML with ever advancing tech-
nology such as the use of droplet microfluidics to
analyse a few thousands of AML single cells [15].
Despite being compelled to technical artefacts such as
high allelic dropout rates and random transcript cover-
age, scDNA-seq is able to resolve the complicated
subclonal structure of AML that cannot be defined
through bulk analysis using variant allele frequencies
(VAF) or inconclusive zygosity states.
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sequencing studies of paediatric and adult AML have
revealed significant age-specific genomic differences
[2,31,34–37] (amongst others which have been reviewed
in detail elsewhere). Adult AML has been classified
with at least 11 genetic classes [34], and over 20 sub-
sets can be assigned when also considering cell differ-
entiation states of the leukaemic blasts [2,38]. Similar
trends in mutated gene co-occurrence and mutational
hotspots are reported in the paediatric population [31];
however, the extent to which the site, frequency and
co-occurrence of specific mutations identified are dis-
tinct from those in adult AML. In brief, in paediatric
patients, mutations in FLT3, NPM1, WT1, CEBPA
and KIT are most frequent, RUNX1, CBFB and
KMT2A (a.k.a MLL) fusions most commonly occur as
well as structural aberrations including trisomy 8 and
loss of the Y chromosome. The incidence of KMT2A-
rearranged AML is much higher in children compared
to adults (38% vs 2%, respectively), with the highest
incidence in infants (77%) [1,6]. Alterations in RAS,
KIT and WT1 genes are more common in children
than adults. In contrast, mutations in DNMT3A and
TP53, which are commonly found in adults, are virtu-
ally absent in paediatric patients. More common muta-
tions in adult AML are NPM1 and genomic
subgroups consisting of AMLs with mutated chro-
matin and RNA-splicing genes (e.g. SRSF2,
DNMT3A, TET2) and class defining IDH2 mutations.
Box 2
Brief overview of AML treatment
A small number of therapies targeted to mutational events and/or genomic profiles have been recently developed for
patients with AML, although the standard of care treatment dates back to the 1970s [16]. The current standard induction
chemotherapy protocols used in AML, often termed ‘3 + 7 regimens’, consist of an anthracycline (daunorubicin or
mitoxantrone) and cytarabine (Ara-C). New therapies for AML are extremely limited and are often only suitable for
specific subgroups of patients, based on synthetic lethality in drug treatments or genetic features. This includes all-trans-
retinoic acid (ATRA) targeted therapy for RAR rearranged AML, FLT3 inhibitors for FLT3 mutated subtypes, IDH1/2
inhibitors for IDH mutated groups and hypomethylating agents. For example, Enasidenib and ivosidenib have been
approved by the Food and Drug Administration in 2017 and 2018 for the treatment of adult relapsed/refractory AML
with IDH2 and IDH1 mutations, respectively. ATRA plus arsenic trioxide (ATO) has recently been approved as
frontline therapy for acute promyelocytic leukaemia (APL) [17]. APL is a type of AML characterised by the PML-RARa
fusion oncoprotein. ATRA and ATO treatment induces the degradation of PML-RARa oncoprotein. Indeed, two
epigenetic compounds azacitidine and decitabine, inhibitors of DNA methyltransferases, have been recently approved
for use clinically in myeloid cancers including AML [18,19]. Many other epigenome targeted compounds are in early
stages of clinical trials for translational application. Moreover, given the inherent reversibility of epigenomic marks [20],
identifying biomarkers, with the help of the molecular profiling tools, that can be exploited for patient prognostics to
particular targeted therapies will be instrumental for making informed decisions in treating AML of distinct subtypes.
More recently, BCL-2 inhibitor venetoclax has been approved for clinical use [21]. It is unclear whether the novel
therapies recently approved for adult AML will be suitable for paediatric cases, at all, or only in a minority of cases given
the distinct genetics, frequencies of mutations and transcriptional profiles of paediatric AML [2225]. Additionally, what
is emerging now in adult AML are features of chemoresistant cells, notably in their transcriptional profiles, that
distinguish them from therapy-na€ıve cells [26,27] and which may be more suitable for therapeutic targeting rather than
the mutation per se. Chemoresistant profiles of AML should be considered in terms of the age the patient and the
associated genetics, given the above mentioned differences in paediatric and adult AML. It is clear that some mutations
and chromosomal aberrations are excellent for minimal residual disease (MRD) monitoring [28,29]. However, it is also
clear that those markers persist following treatment as in the case of RUNX1-RUNX1T1 in the absence of clinical
manifestation of the disease. Designing novel therapies that target the chemoresistant transcriptional profile that could
be combined with the mutation/fusion protein targeting drug or used as an alternative to standard chemotherapy is
worth considering. In a recent study of primary chemotherapy resistance in a cohort of 107 children and adults with
AML using targeted gene sequencing, it was shown that few patients exhibited specific individual mutations associated
with primary chemotherapy resistance and failure of induction chemotherapy [30]. Therefore, it appears that additional
genetic or molecular mechanisms mediate chemotherapy resistance in paediatric and adult AML.
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The frequency of adult patients with RUNX1, CBFB
and KMT2A fusions is low, whereas complex kary-
otypes are frequent. FLT3 mutations commonly occur
across the age groups, with similar frequency. How-
ever, unique and paediatric-specific FLT3 variants
have been reported [39].
Changes in the epigenetic landscape are a feature of
adult AML, and various regulators for the AML epi-
genome are subjected to mutation, deletion and chro-
mosomal translocation [41]. Examples of epigenetic
variations include cytosine methylation patterning, his-
tone proteins alterations and RNA-associated gene
silencing [20]. Multiple epigenetic profiling efforts have
observed recurrent mutations in genes that govern
these processes such as DNMT3A, TET2, IDH1/2,
although they arise fewer in children than in adults
and are usually early events in leukaemogenesis [22].
Associated with specific genetic subgroups are distinct
transcriptional states [42], and in this report, we will
highlight transcriptional profiling in paediatric and
adult AML.
3. Transcriptional profiles of
paediatric and adult AML
There is a growing list of data sets of transcriptional
AML profiles, and we have highlighted some that are
publically available that we have mentioned in this
review (Table 1 contains a nonexhaustive list, Fig. 2).
One of the limiting factors in assessing the distinct
molecular features of paediatric and adult AML is the
availability of data sets that contain AML specimens
across the age continuum or of data sets that contain
comparable AML subgroups from adults and children.
Comparative analysis across different platforms (e.g.
microarray and RNA-seq, see Table 1 containing a
representative list for available data sets) is possible
but does come with additional computational limita-
tions. Recently, a large data set that enables compara-
tive analysis of AML across the ages has been made
available: Tyner et al. published on the BEAT AML
cohort (Box 4) consisting of 572 AML patients across
the age continuum (18 patients < 19 years, 54 patients
20–35 years, 136 patients 36–55 years, 141 patients 56–
65 years and 207 patients > 66 years) [33].
The use of mouse models to address the molecular
differences between paediatric and adult AML is
equally challenging, given the myriad of biological
variables that should be considered in the experimental
set-up, even within a defined genetic subgroup, includ-
ing age-specifications for cell of origin, cell hierarchy,
cell surface marker expression, cell cycle, microenvi-
ronment and localisation. Nevertheless, mouse models
featuring specific genetic AML features (i.e. NUP98-
HOXA9, ETO2-GLIS2) have shown that paediatric
and adult AML are distinct biological entities, depend-
ing on the age of the cell of origin and whether it is of
fetal or adult origin [23,43]. The data suggest that the
transcriptional programming within the cell of origin
(fetal or adult) can explain the differences in paediatric
and adult disease development. Indeed, it has been
speculated that the in utero mutational acquisition
(such as GATA1s mutation in trisomy 21-AML) may
have to do with the transcriptional state in the fetal
liver, as this mutation does not occur later in life
[44,45].
4. Metabolic profiles of paediatric and
adult AML
Distinct metabolic alterations have been increasingly
reported in adult AML following the advent of meta-
bolomic profiling (Box 5). For example, a study con-
ducted by Chen et al. identified an altered glucose
metabolism signature in adult patients with AML, in
which six associated glucose metabolism markers were
described to significantly inform upon patient progno-
sis. However, this phenomenon has not yet been
reported among paediatric cohorts [46]. Of note,
IDH1/2 mutated adult AML has been described to
Box 3
Mutational Profiling
It is common that AML patients exhibiting similar
clinical presentations have substantially different muta-
tional aberrations with varying clinical outcomes to
therapies [40]. In 2017, the European LeukaemiaNet [2]
factored in the significance of mutational events in
AML and improved the predictive strategy for response
to therapy and survival by adding recently recognised
mutations in RUNX1, ASXL1 and BCR-ABL1 to the
known risk contribution delimited by mutations in
NPM1, FLT-ITD, CEBPA and TP53. Within this risk
stratification system, patients are classified according to
the cytogenetic and molecular characteristics into three
prognostic classes – adverse risk, intermediate risk and
favourable risk. However, there could be many more
genes that could be substantial for leukaemia develop-
ment as well as apprise the appropriate therapies for
individuals, and the fast advancing molecular profiling
assays hold the power to delve into and discover these
genes.
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drive aberrant perturbations in the tricarboxylic cycle
through the reduction of alpha-ketoglutarate to the
oncometabolite 2-hydroxyglutarate [47]. Comparatively,
AML internal-tandem duplications (ITD) in the FLT3
gene confers dependence on aerobic glycolysis via a
marked upregulation of the mitochondrial gate keeper
enzyme, hexokinase-2 [48]. To date, few studies have
attempted to investigate the metabolome of paediatric
AML. As a result, there is currently a gap in our
knowledge of metabolic vulnerabilities significant to
paediatric AML that could guide future lines of pre-
clinical investigation for targeted treatment. Further-
more, the uncontrolled growth of leukaemic cells and
the development of chemoresistance is now increas-
ingly affiliated with the systemic supply of nutrients
for amino acid and fatty acid metabolism [49,50].
Homing in on the stark alterations in metabolism
between leukaemic cells and ‘normal’ haematopoietic
cells currently represents a promising avenue in
patient diagnosis and the development of more tar-
geted and personalised therapies [51–53]. Research
into novel AML therapies has highlighted the contri-
butions of cellular metabolic adaptations in promoting
both resistance to conventional chemotherapy and tar-
geted inhibition in leukaemic cells [54].
Fig. 1. Schematic illustration of the skewed pattern of AML incidence rates (cases/year) and the distinct cytogenetic and molecular features
that exist across the age-spectrum.
Box 4
BEAT AML
The Beat AML program involved 11 academic medical
centres who worked collectively to accrue a cohort of
~ 950 AML patient specimens and 11 pharmaceutical
and biotechnology companies, who supplied drugs for
testing. These specimens were subjected to whole exome
sequencing, RNA sequencing and ex vivo drug sensi-
tivity analyses. The majority of this data set was
published in October 2018 in Nature [33]. The authors
provided detailed clinical annotations, genomic and
transcriptomic analyses and ex vivo drug sensitivity
studies, and analytical approaches for data integration
and accessible through the Beat AML data viewer
http://www.vizome.org/).
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5. Clonal heterogeneity and
chemoresistance in adult and
paediatric AML
Although AML can be preceded by CH, most of CH
clones are not ‘preleukaemic’ and will never transform
to AML. Distinguishing benign CH from preleukaemic
CH is a clinical goal in order to prevent AML trans-
formation. Recently, p53 conformational changes in
WT p53 DNMT3A mutant clones were shown to dis-
tinguish benign CH from true preleukaemia (EHA
abstract S133, 2020, Tuval and Schlush). The number,
identity and burden of mutations in CH are associated
with the risk and timing of progression to AML
[57,58]. Common CH-associated mutations include
DNMT3A, TET2 and ASXL1 (‘DTA’ mutations) and,
despite being found in AML, are not helpful for MRD
monitoring as these DTA mutations are not lost even
in remission [28]. Somatic aberrations that disrupt the
cytosine methylation system (epigenetic) such as muta-
tions in DNMT3A and TET2 occur in preleukaemic
cells early and may give proliferative favour, but are
inadequate in causing the disease [59]. AML initiating
mutations in the NPM1 gene, however, do manifest in
AML [60] and are neither preleukaemic nor CH-re-
lated. Thus, MRD monitoring of NPM1-mutant
clones may be combined with analysis of prevailing
preleukaemic mutations in clones at remission to
objectively enhance or even replace therapy-na€ıve
genomics to predict clinical outcomes [29,61]. ‘Preleu-
kaemic’ clones arise with surprising frequency during
fetal development also. The in utero acquisition of
leukaemogenic fusions involving the KMT2A and
RUNX1 genes [62,63] is frequently seen, at a much
higher rate, however, than the development of child-
hood AML with these fusions. This indicates clonal
expansion of cell populations with these leukaemic
fusions, which are not sufficient for disease develop-
ment. This has been supported by transgenic studies,
for examples those showing a lack of disease with
RUNX1 fusions without additional mutations [64].
Indeed in the case of RUNX1-RUNX1T1 fusions, it is
known such clones can persist for years in the absence
of disease, such as in patients that have received treat-
ment for RUNX1-RUNX1T1-positive AML and
remained in remission despite the persistent detection
of RUNX1-RUNX1T1-positive cells [65,66].
The subclonal architecture of AML at diagnosis and
relapse has been modelled by several groups in an
attempt to understand both the evolution of the dis-
ease and the factors contributing to treatment resis-
tance [67–69] (Fig. 4A). Using NGS on AML patients
of FLT3-ITD-specific subgroup at three different time
points, diagnosis, complete remission and relapse
revealed that clonal evolution occurred in either two
ways – (a) a dominant clone that acquired new
somatic aberrations due to DNA damaging therapeutic
agents and expanded in relapse or (b) subclones pre-
existing in low numbers at diagnosis evaded killing
and prevailed as the dominant clone at relapse [70].
Lineage tracing of DNA barcodes of adult AML
cohort combining exomic, transcriptomic and pheno-
typic profiling revealed a group of preordained bar-
coded clones with common molecular ancestry
constituting gene expression or functionally construed
stemness and chemoresistant properties that are posi-
tively selected upon chemotherapy exposure [71].
A greater number of paediatric patients present with
de novo AML than in adults and rarely have the com-
mon adult mutations such as DNMT3A and TET2 [5]
suggesting that a difference in clonal heterogeneity
between adult and paediatric cases may be explained
by the genetic mutations. The TARGET initiative
study applied whole exome sequencing on 20 de novo
paediatric AML cases following matched trios of sam-
ples at diagnosis, complete remission and relapse and
highlighted compelling clonal evolution and diversity
with persistence (diagnostic VAF > 0.4), loss (diagnos-
tic VAF < 0.2) and gain of molecular events using
sequence and copy number alterations data, as shown
in adult AML data [32]. McNeer et al. [72] (another
TARGET initiative study on paediatric AML)
employed whole-genome and RNA sequencing found
that AML groups with genetic clones bearing initiation
mutations such as NUP98-NSD1 collude with muta-
tions in FRMD8, WT1 and others to prevail and may
correlate with causing chemoresistance, whereas sub-
clones with mutations in FLT3 and NRAS were eradi-
cated by chemotherapy and thus are not associated
with disease relapse after chemotherapy. Since there is
a lack of research on clonality and chemoresistance in
paediatric AML, it is exciting to anticipate what future
studies that specifically quantify age-related clonal
diversity may bring.
Intratumoral heterogeneity has been extensively
studied using cell surface markers [73]. However, this
approach relies on predefined markers that may not
accurately represent underlying transcriptional pro-
grammes nor accurately represent paediatric AML
heterogeneity. Recently advances in single-cell RNA-
sequencing (scRNA-seq) technologies have enabled the
analysis of single-cell transcriptional states together
with the genetic background [67]. In this paper, the
authors present methods for amplifying barcoded tran-
scripts of genes that are frequently mutated in AML.
AML cells could be distinguished into AML cell types
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and differentiation states and importantly could be
separated from normal cells. Over the clinical course
however following treatment, their identity as normal
or malignant required adaptation of the methodology
and it had to be assumed that the mutation was pre-
sent postchemotherapy as well as at diagnosis. It could
be argued that clones/single cells that emerge
postchemotherapy may not have the diagnostic muta-
tion and are therefore missed by this assumption. For
example, FLT3 mutations are unstable and can be
gained or lost as the disease progresses, with patients
exhibiting FLT3 status shift from diagnosis to relapse
in 1–30% cases [2,74,75]. Indeed, mutations of FLT3
exhibited relative depletion by chemotherapy in AML
induction failure suggesting that its subclonal evolu-
tion in and of itself does not cause chemotherapy resis-
tance. Rather, its activation in combination with
specific other pathogenic events as part of distinct
clones such as those with mutations of WT1 or
NUP98 rearrangements or others may cause resistance
to chemotherapy.
Significant advances have been made in identifying
geneticially and transcriptionally distinct AML subclones
Fig. 2. Exemplar for pathway analysis workflow. After differential expression analysis the list of differentially expressed genes can be used
for GSEA as a preranked gene list (other input options are also available). Depending on your research interests, one or more gene sets can
be selected and GSEA will calculate a score reflecting whether each gene set is overrepresented at the extremities of the ranked gene list.
The graph shows the enrichment profile, and the enrichment score (ES) is the point furthest from zero. ES values, normalised ES, false
discovery rate and other information are contained in the results report.
Box 5
Metabolic profiling
Metabolic reprogramming is a common cancer cell
phenotype in which neoplastic cells acquire vast
amounts of energy and metabolites to sustain uncon-
trolled growth and proliferation. Driven by an array of
extrinsic bone marrow (BM) microenvironmental cues
and intrinsic malignant cell factors, metabolic repro-
gramming has given rise to a range of context-specific
metabolic phenotypes [55]. Metabolomic profiling is
emerging as a systemic technology that focuses on the
comprehensive and semiquantitative analysis of
metabolites and small molecule intermediates within
specific cells, tissues and other biological specimens [56].
Metabolomics platforms, including proton nuclear
magnetic resonance spectroscopy and mass spectrome-
try, have provided a robust and innovative approach to
study the AML metabolome through the characterisa-
tion of by-products that reflect biologically relevant
changes in cellular state.
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using an unbiased proteomic analysis of CD34+ AML-
specific plasma membrane proteins [76]. Using this
approach, clones that could be distinguished based on
surface membrane expression of CD25 or IL1RAP could
be separated into distinctly evolved clones that had
acquired different additional mutations and different
transcriptional profiles, notably in metabolic pro-
grammes such as ROS, OXPHOS and glycolytic path-
ways.
6. Adult and paediatric AML
leukaemic stem cells and
chemoresistant cells
6.1. LSC profiles and prognostic value in adult
and paediatric AML
AML arises from and is maintained by LSCs [4]. LSCs
have been defined by a number of characteristics and in
adult AML through the use of xenotransplantation
approaches. These include cell surface marker expression
(e.g. CD34 and CD38, with many more still being discov-
ered), enhanced/acquired self-renewal, slow cycling or
quiescence, serial engraftment and distinct biochemical
features (reviewed in Ref. [77]). Biochemically, AML
LSCs defined by cell surface markers or quiescence have
low levels of reactive oxygen species (ROS) compared
with the bulk blast cycling AML population [78–80].
Therapy-na€ıve quiescent LSCs are characterised by a low
rate of energy metabolism with low ROS levels and low
mitochondrial oxidative phosphorylation (OXPHOS)
dependent on BCL-2 levels and amino acid metabolism
compared to bulk AML blast cells [26,78]. In contrast,
the bulk AML blasts present high glycolytic metabolism
affecting cell proliferation and cell survival pathways
(Fig. 3) [46,81]. ROS-low defined LSCs are unable to
upregulate glycolysis and therefore have an increased
sensitivity to strategies that block OXPHOS [82,83]. Such
features are being targeted in order to eradicate the AML
LSC, an approach thought to achieve improved out-
comes for AML. In fact, LSC frequency and associated
transcriptional signatures carry clinical prognostic
impact and have been extensively associated with adult
AML chemoresistance and leukaemia relapse [84–87].
However, there remains a paucity of studies defining
true LSCs specifically in paediatric AML for their
eradication. It is common practice to extrapolate from
adult studies onto paediatric AML, for example when
characterising LSCs using cell surface markers or
cycling properties [2,28] for their biochemical and
molecular analysis. Using aberrantly expressed cell sur-
face markers within the CD34+/CD38/low fraction of
paediatric AML patients, LSCs were found to be present
at a higher frequency at diagnosis in patients who are
more likely to fail treatment regimens [88]. A panel of
LSC markers in both paediatric and adult AML is neces-
sary given their heterogenous expression, and therefore,
sensitivity of LSC frequencies is dependent on the panel
used [89]. We are still learning the use of LSCmarkers for
detecting MRD with flow cytometry, and this is being
addressed in the paediatric AML Myechild clinical trial
(NCT02724163). It is worth considering though that in
the absence of definitive xenotransplantation experi-
ments with LSCs defined using cell surface marker
expression from paediatric AML, and specifically from
the distinct subgroups of AML found in the paediatric
population, that important paediatric-specific features
may be masked. For example, one of the most common
AML subgroups in the paediatric population, namely
MLLr AML, has been distinguished for the presence of
cycling, CD93-positive LSCs within the typically gated
CD34+CD38 LSC population. However, these findings
were reported in a patient cohort that had an average age
of 51, with the youngest patient 18 years [90]. We can
extrapolate but cannot be definitive that this is true for
paediatric MLLr AML. Moreover, adult LSC function-
ality has also been found in the CD34 fraction [91];
therefore, caution is warranted when assigning and
extrapolating LSC characteristics from adult to paedi-
atric AML.
Molecularly, the transcriptional state of the adult
AML LSCs distinguishes them from the bulk blast
population and nonmalignant HSCs. Microarray tran-
scriptional analysis of adult LSCs was used to estab-
lish and validate a 17-gene stemness score developed
using adult outcome data (LSC17) [85]. It is important
to note that this score was developed using xenotrans-
plantation of CD34+/CD38+/ sorted fractions. The
LSC17 score could predict disease outcome in adult
patients with AML in TCGA validation cohorts that
contain both microarray and RNA sequencing [60]
and could notably also predict disease outcome in the
paediatric ELAM02 cohort [92], based on the assump-
tion that paediatric and adult LSCs share common
gene expression programmes. The clinical utility of the
LSC17 score is being trialled with a Nanostring plat-
form assay to determine prospectively the feasibility
and prognostic power of LSC17 score testing in newly
diagnosed AML patients [93]. Use of a weight-adapted
LSC17 subscore specific for some subsets of risk
groups, as, for example, a low molecular risk groups
with a poorer prognosis [94] is anticipated to poten-
tially identify patients with a higher risk of drug resis-
tance at diagnosis that may benefit from novel upfront
treatment strategies. This is particularly promising, as
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predicting therapy resistance to standard therapy in
AML patients has been very difficult even with more
recent mutational and cytogenetic information [95].
A paediatric 6 gene LSC score (pLSC6) was recently
developed [96] using microarray data from 163 paedi-
atric patients that included the most common paedi-
atric subgroups (i.e. core-binding factor groups,
MLLr). The pLSC6 score was selected starting from
the same 48 LSC gene pool that were used to generate
the adult LSC17 score. Therefore, the pLSC and adult
LSC17 scores have four genes in common. The pLSC6
score has been validated with the RNA-sequencing
data from the TARGET database (Box 6), where it
showed improved prognostic performance compared
to MRD- and molecular-based risk classification, as
well as compared to LSC17. Future studies directed
towards generation of gene expression profiles in the
fraction of paediatric LSCs that have been functionally
defined (whether these are exclusively within the
CD34+/CD38+/ subset or not) is warranted to fur-
ther refine the gene expression score specific to paedi-
atric AML, especially as the prognosis of paediatric
AML is typically better than that of adult AML.
6.2. LSCs as therapeutic targets
There have been some examples of success in develop-
ing anti-LSC compounds [99–103]. The approach in
general includes using the therapy-na€ıve LSC tran-
scriptional profile that distinguishes LSCs from the
bulk AML cells and from normal HSCs. Useful data
sets for such approaches include those from LSC
Fig. 3. Schematic representation of cellular and metabolic changes in adult AML following chemotherapy. (A) At diagnosis, AML comprises
a molecularly heterogeneous population of cycling and quiescent LSCs and bulk AML blast cells. Treatment with conventional
chemotherapy often results in complete remission; however, there many remain small numbers of leukaemic cells that are chemoresistant
giving rise to what is termed ‘minimal residual disease’ (MRD). The MRD chemotherapy-resistant LSC population possess the ability to re-
initiate leukaemia and potentiate disease aggressiveness through further acquisition of molecular heterogeneity. (B) The associated
metabolic programmes of LSCs and bulk cells are dynamic and vary based upon therapy status. Initially, both therapy-na€ıve quiescent and
cycling LSCs are highly sensitive to chemotherapy: Therapy-na€ıve quiescent LSCs have low ROS levels and OXPHOS dependent on high
BCL-2 levels when compared to cycling LSCs and bulk AML cells, of which also depend on aerobic glycolysis. Cells which remain
postchemotherapy, therapy-resistant, have notably higher ROS levels, high OXPHOS and FAO when compared to therapy-na€ıve AML cells.
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populations that have been validated by xenotrans-
plantation and tightly linked to poor survival in AML
and failure of standard therapy across all AML sub-
types [84,85]. By querying these signatures against a
repository of drug candidates, it is possible to identify
relevant candidates that could be repositioned for use
in AML. Examples include compounds such as anti-
histamines, cardiac glycosides and glucocorticoids [99].
With regard to chemosensitivity in specific AML cyto-
genetic and mutational subgroups, there has been
recent advances from the BEAT AML cohort [33]. Of
particular note, there was a strong association between
mutations in NRAS and MAPK sensitivity which is
interesting as NRAS mutations are found commonly
in paediatric and adult AML. More adult AML-asso-
ciated IDH2 mutations conferred sensitivity to a broad
spectrum of drugs, whereas mutations in IDH1 con-
ferred resistance to most drugs. Mutations in RUNX1,
again commonly observed in paediatric and adult
AML, correlated with sensitivity to PIK3C and mTOR
inhibitors (such as BEZ235) and to the multikinase
vascular endothelial growth factor receptor (VEGFR)
inhibitor, cediranib.
Another approach in developing novel therapeutic
strategies is to use the mRNA expression profile
induced upon oncogene expression (e.g. MLL-AF9,
HOXA9 and MEIS1) to screen using Connectivity
Maps [104] to identify clinically approved drugs that
may revert an early leukaemic transformation gene sig-
nature. Histone deacetylase inhibitors were identified
in this way [105], which have proved to be good com-
bination therapeutic approaches in adults with AML.
Interestingly, antihistamines again were found to have
antineoplastic effects via disruption of lysosomal and
mitochondrial homeostasis [106]. This link with meta-
bolism is interesting, given the emerging role of meta-
bolic reprogramming in chemotherapy resistance in
AML that will be discussed below.
6.3. Molecular profiles of chemoresistant cells
Until recently, the LSC subpopulation was viewed as
the main source of chemoresistant cells. It has been
shown that LSCs are relatively resistant to standard
therapies [107–109] and responsible for driving disease
relapse. Therefore, LSCs were pointed out as a clini-
cally relevant therapeutic target for improving AML
outcomes. Furthermore, chemoresistant cells were
identified as CD34+CD38 cells within the osteoblast-
rich endosteal region of the BM [109]. In this paper,
global transcriptional analysis of the LSCs that were
serially xenotransplanted was used to define features
that enabled LSC activity, but not features of
chemoresistance. Therefore, it is clear that LSC molec-
ular profiles are stable through xenotransplantation
but whether these are the features that result in disease
relapse is still a matter of discussion. The question
remains whether cells adapt their transcriptional pro-
files following exposure to chemotherapy or whether
there are inherent features in a clone of cells, that may
or may not be within the therapy-na€ıve LSC compart-
ment responsible for chemoresistance.
Some light has been shed on the chemoresistant cells
using postchemotherapy transcriptional profiling. We
now know from adult AML studies that functionally
and phenotypically defined LSCs are not enriched with
chemotherapy-resistant cells [26,27,110]. Indeed it was
shown that LSCs are not resistant to standard
chemotherapy [26]. The cells that remain
postchemotherapy are distinct from therapy-na€ıve
LSCs; chemoresistant adult AML cells are strongly
driven by cellular metabolism displaying a dependence
on fatty acid oxidation (FAO) together with elevated
ROS and OXPHOS and a mRNA signature distinct
from therapy-na€ıve LSCs (Fig. 4B). However, these
signatures are temporary, as the cells that are detect-
able at a clinical relapse stage lack these signatures. It
remains to be shown whether such chemoresistant cells
re-acquire the therapy-na€ıve LSC transcriptional state
at relapse. These molecular features highlight a win-
dow of opportunity that exists to target the molecular
state of the chemoresistant cell prior to onset of
relapse. Targeting mitochondrial oxidative metabolism
with OXPHOS inhibitors redirects metabolism towards
glycolysis and sensitises resistant cells to standard
chemotherapy [26]. Another study showed that inhibi-
tion of myeloperoxidase sensitised chemoresistant
Box 6
TARGET
The Therapeutically Applicable Research to Generate
Effective Treatments (TARGET) initiative employed
comprehensive molecular characterisation to determine
the genetic changes that drive the initiation and
progression of hard-to-treat childhood cancers. TAR-
GET researchers utilised various sequencing and array-
based methods to examine the genomes, transcriptomes,
and for some diseases epigenomes of select childhood
cancers. This ‘multi-omic’ approach generated compre-
hensive profiles of molecular alterations for each cancer
type [31,32,97,98].
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AML cells to chemotherapy by impairing OXPHOS
and cellular energetic balance, triggering oxidative
damage and sustaining oxidative stress [111]. The
chemoresistant molecular signature links to clinical
outcomes in adult AML relapse [26,27]. Whether this
transient transcriptional state is similarly seen in paedi-
atric AML subgroups remains an open question and is
most likely different based on the cytogenetic and
mutational profiles of the adult AML specimens in
those studies, which are not the common paediatric
subgroups.
One subgroup of AML patients where biochemical
data relating to chemoresistance may be more reliably
extrapolated is the FLT3 mutated subgroup. FLT3
mutations occur at a similar frequency in ~ 30% of
AML patients across the age-spectrum and is associ-
ated with an inferior prognostic outlook [112]. The
AML FLT3-ITD mutation has been described to
potentiate the Warburg effect, a well-characterised
phenomenon within the field of cancer biology that
describes the marked dependency of malignant cells
on aerobic glycolysis over OXPHOS [48]. Hence,
Fig. 4. Simple diagrammatical display of de novo AML clonal evolution and distinction of gene signatures between therapy-na€ıve cells and
chemotherapy-treated cells. (A) The leukaemia-initiating (founding) clone contains AML pathogenic somatic mutations; among the founding
clone, one subclone is eradicated by the chemotherapy whilst the other with relapse-initiating mutations accumulated further mutations to
evolve into a dominant clone at relapse. HSC (adapted from [13]). (B) Molecular signatures, such as therapy-na€ıve leukaemia stem cell (LSC)
signatures, LSC17 [85] and stemness [84], leukaemic regeneration cell signature [27] and chemoresistance signature [26], are discrete
between therapy-na€ıve LSCs and leukaemic cells after exposure to chemotherapy during the course of disease in adults. These signatures
permit the identification of therapy-na€ıve LSCs and the discrimination between impending relapse vs durable disease-free survival in human
AML patients during remission states. The status of these signatures in relapse patients is not yet well defined.
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FLT3 mutational status represents an attractive focus
for the development of future therapies in which subtype-
specific metabolic vulnerabilities can be exploited. Of
note, therapeutic intervention with the glycolytic inhibi-
tor 2-deoxyglucose (2-DG) has been reported to induce
cell death and exert antiproliferative effects in FLT3-ITD
AML in vitro through a marked inhibition of aerobic gly-
colysis. Interestingly, 2-DG-induced inhibition of glycol-
ysis has also been documented to potentiate the
cytotoxicity of conventional Ara-C chemotherapy as well
as restoring chemosensitivity in therapy-resistant FLT3-
ITD AML cells [48,113]. Despite the promise of these
findings, results are primarily based upon observations in
cell lines. Thus, inhibiting glycolysis warrants further
investigation to define the clinical applicability in large
cohorts of both paediatric and adult FLT3-ITD AML
patients.
As part of the TARGET initiative, whole-genome
DNA and RNA sequencing was performed on a
cohort of paediatric AML patients that failed induc-
tion chemotherapy [72]. Distinct and invariant gene
expression programmes before and after chemotherapy
were seen, as well as diverse forms of clonal evolution
upon chemotherapy exposure. Consistent with adult
data, there was a relative depletion of clones with
FLT3 mutations. Unsupervised hierarchical clustering
of gene expression profiles did not segregate with
genetically defined groups. However, Gene Set Enrich-
ment Analysis (GSEA) analysis of primary chemoresis-
tance included programmes positively enriched for
OXPHOS, FAO, ROS, G2M checkpoint, MYC tar-
gets and E2F targets.
Another contributor to chemoresistance is the BM
niche, which changes considerably with age [114],
[115]. It has been established that the BM niche sup-
ports leukaemic cell metabolism pathways leading to
leukaemia chemoresistance [116,117]. Of note,
chemoresistance via interaction between the BM mes-
enchymal stromal cell and the AML blast cell could be
abrogated using an approach that extinguishes energy
metabolism in the blast cell [118]. This link with
energy metabolism is a common theme with recent
chemoresistance insights.
7. Conclusions and Perspectives
Challenges remain including assessing the correlations
between leukaemia-specific markers across the differ-
ent cytogenetic and mutational subgroups in adult
and paediatric AML, not only in identifying the sur-
face markers that can aid subclone identification but
also MRD detection that could be used to guide
patient-specific treatment strategies, which potentially
involve targeting the leukaemia-specific transcriptional
and metabolic programmes. It is clear that paediatric
AML is a disease distinguishable from adult AML with
regard to the gene mutation spectrum. However, current
risk stratification approach only includes common muta-
tions based on prognostic values when the total number
of discovered mutations surpasses that. It may be more
clinically significant to consider allelic burden profiles of
AML-associated mutations (e.g. targeting genomic
abnormalities with high diagnosis VAF) in order to
decide on targeted therapies and risk categorisation. It is
also important to closely study novel mutations and tran-
scriptional profiles post-therapy so as to gain perspectives
on clonal evolution and instrumentation to relapse.
Indeed, targeted sequencing of known mutations is limit-
ing and may not be optimal for advanced disease, ther-
apy-related and secondary disease or for paediatric
subgroups. The ensuing interpretation of the molecular
profile in AML patients across the age range and most
critically at different phases of disease (i.e. diagnosis,
remission and relapse) can be prominent in better appre-
ciating the disease pathogenesis and promise an improve-
ment in patient management approaches. Moreover,
conventional combination therapies to target the chi-
meric clonal subpopulations have a possibility of precari-
ous effects since either pre-existing or acquired therapy-
resistant clones could proliferate and prevail to result in a
fatal relapse. Transcriptional profiling has revealed sig-
nificant and targetable features of AML cells and being
able to identify and specifically kill these chemoresistant
clones is the current challenge. Efforts across the globe
including Genomics England are endeavourering to bring
together ‘omic’ profiling and clinical data to better
inform on best treatments for individual patients.
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